SR11237

SR11237 (BMS-649) is a potent retinoid X receptor (RXR) -selective agonist that is devoid of any RAR activity. SR11237 can cause RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element[1][2][3].

Product Specifications

CAS Number

[146670-40-8]

Product Name Alternative

BMS-649

UNSPSC

12352005

Target

RAR/RXR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sr11237.html

Purity

99.91

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1(C2=CC(C3(C4=CC=C(C(O)=O)C=C4)OCCO3)=CC=C2C(C)(C)CC1)C

Molecular Formula

C24H28O4

Molecular Weight

380.48

References & Citations

[1]Gendimenico GJ, et al. A pleiotropic response is induced in F9 embryonal carcinoma cells and rhino mouse skin by All-trans-retinoic acid, a RAR agonist but not by SR11237, a RXR-selective agonist. J Invest Dermatol. 1994;102 (5) :676-680.|[2]Dupuis H, et al. Exposure to the RXR Agonist SR11237 in Early Life Causes Disturbed Skeletal Morphogenesis in a Rat Model. Int J Mol Sci. 2019;20 (20) :5198. Published 2019 Oct 20.|[3]H.L. Dupuis. The RXR agonist SR-11237 affects skeletal development. ABSTRACT ONLY| VOLUME 24, SUPPLEMENT 1, S147, APRIL 01, 2016.